Searched for
INVAGEN PHARMA
Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...
- ET Businesswoman of the Year 2021: Samina Hamied - The woman who carries forward a storied legacy, seeking profit, but never at the cost of values“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,00...
- Cipla US business gains traction: Q3 takeawaysEarnings per share of the pharma major, with a face value of Rs 2 each, stood at Rs 4.12.
- Current headwinds to help shape M&A contours for Indian pharmaDrugmakers have reported impairments, reduced revenue guidance, or stretched the payback time.
- Cipla at the bottom end of margin in industry: Umang Vohra, MD & Global CEOFor the leverage to be more in the future, we need to have more unlocking in the US pipeline, which is what most analysts are also saying.
- Rupee may hit 70 sooner than later; five export-oriented stocks to bet onExperts believe export-oriented sectors such as information technology, pharma, textile and others will get some fillip amid rising global ...
- FDA norms punch a Rs 5,000 crore hole in Pharma IndustryIn FY16, the top five — Sun Pharma, Dr Reddy’s, Lupin, Aurobindo and Cipla — ran up a total bill of Rs 3,497 crore in legal and professiona...
- With several firms getting USFDA clearances, Street to breathe easy about pharma stocksLast week, Lupin, Cadila Healthcare and Alembic Pharma received clearances from the US regulator for their key facilities.
- Indian pharma takes M&A route to build a global footprintLast week Dr. Reddy's acquired a portfolio of eight complex generics in the US from Teva in a deal worth $350 million.
- Even after poor results, Cipla stock may just be the right pick nowThe US business is 20% of total revenues. As the proportion of this high-margin business grows, it will help Cipla improve profitability.
- Cipla should launch 10 odd products in the FY17: Umang Vohra, Global COO"Cipla FY16 guidance of 20-22 per cent revenue growth and 100 to 150 bps margin improvement for this year does not include InvaGen"
- Cipla drug launches hold promise for FY17, grows in prescription businessGenerics sales in the US, launch of inhalers in the UK and a ramp up from its acquisitions are key positive factors to look forward to.
- Twelve stocks in focus in Wednesday's tradeIndian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.
- Analysts bet on Cipla as acquisitions expected to boost company's growthAcquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla set to buy American business of Hetero Drugs for $550 millionPeople close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.
- Generic vs generic: Drug cos battle to protect turfGeneric drug makers, which have typically waged legal battles against innovator pharma giants, are now suing each other to protect their ma...
- Ranbaxy ties up with US coPharma major Ranbaxy Laboratories Ltd has entered into a strategic partnership with US-based Invagen Pharmaceuticals Inc.
Load More
